Media about us

28 October 2016

Corneal Inlays Better Than Monovision, Researchers Say

Marcia Frellick / MedScape

One of the biggest misperceptions about corneal inlays is that the end result is monovision, experts said here at the American Academy of Ophthalmology (AAO) 2016 Annual Meeting. This is not true, according to Greg Parkhurst, MD, chief executive officer of Parkhurst NuVision in San Antonio, Texas, who is a principal investigator on clinical trials of the Raindrop Near Vision Inlay (ReVision Optics).

19 October 2016

Chairman highlights 2016 industry highlights at OIS

Healio

The past year has seen a number of important approvals and promising study progress in both biotechnology and ophthalmic devices, Emmett T. Cunningham Jr., MD, PhD, MPH, told the more than 900 attendees at the Ophthalmology Innovation Summit in his “Chairman’s 2016 Year in Review.”

19 October 2016

Liquid biopsy open database created under Cancer Moonshot, as pharma joins the fray

Stacy Lawrence / Fierce Biotech

Twenty stakeholders, including major biopharmas, diagnostic players and academic institutions, have committed to creating what they expect will be the largest liquid biopsy open database for cancer genomic profiling data. It’s part of the broader ongoing Cancer Moonshot effort led by U.S. Vice President Joe Biden.

19 October 2016

White House To Announce Big Push For Cancer Blood Tests

Matthew Herper / Forbes

The White House, as part of the Cancer Moonshot effort being run by Vice President Joe Biden, is announcing a major push to develop blood tests that can detect and monitor cancer, that aims to unite makers of diagnostic tests, drugs, and other cancer-related products.

18 October 2016

Brian Dovey: “Devices are less profitable investment targets than medicines”

Elena Krauzova / Forbes

Does Russia have a chance to develop biotechnology, how innovation in biomedicine is born and how cure for cancer is developed? All this and many other things  was covered in Forbes interview with Brian Dovey, managing partner of venture fund Domain Associates, one of the founders and member of the Board of Directors of the Russian pharmaceutical company "NovaMedica".

14 October 2016

Biotech IPOs slow in Q3 despite improvement in general markets

Peter Winter / BioWorld

Biotech IPOs were sluggish in the third quarter, with only seven companies successfully completing their offerings on U.S. exchanges, raising a collective $396 million in the process, according to BioWorld analysis. That was 42 percent below the 12 biotech IPOs, raising $1.35 billion in the third quarter last year and 36 percent off the 11 companies completing their offerings in the second quarter this year, raising $564 million. 

05 October 2016

Raindrop Receives FDA Approval

Maria Scott, MD / Ophthalmology Management

This year, I celebrated my20th anniversary of laser vision correction. I first needed glasses for myopia when I was 12, but only wore them in emergencies because I didn't want to look “nerdy.” At age 16, I got gas permeable lenses, which I loved, and later, laser vision correction, because I hated wearing glasses.

27 September 2016

Two New Corneal Inlays Increase Options for Presbyopia

Roger F. Steinert, MD / MedScape

Until recently, the go-to options for treating presbyopia were reading glasses, monovision with either a contact lens or laser vision correction, or multifocal intraocular lenses. Today we now have one more arrow in our quiver: the corneal inlay, which offers patients a safe, less invasive, and reversible alternative to laser vision correction and intraocular lenses.

20 September 2016

Allergan Buys Liver Drug Maker Tobira for Up to $1.7 Billion

Doni Bloomfield / Bloomberg

Allergan Plc agreed to buy Tobira Therapeutics Inc. for as much as $1.7 billion to gain a late-stage experimental drug to treat liver diseases, one of the most anticipated categories in biotechnology.

Say what? Allergan just agreed to pay a 6X cash premium for Tobira and its troubled PhIII NASH drug

John Carroll / ENDPOINTS

A couple of months after a trial setback crushed Tobira’s share price, Allergan has swooped in to buy the company for $29.35 a share and up to $49.84 a share in contingent value rights if its late-stage NASH drug turns out to be a hit.